Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy

References

• FischerKBahloJFinkAMLong-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trialBlood20161272 208 21526486789
   PubMed Web of Science ®Google Scholar
• HallekMFischerKFingerle-RowsonGInternational Group of InvestigatorsGerman Chronic Lymphocytic Leukaemia Study GroupAddition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialLancet20103769747 1164 117420888994
   PubMed Web of Science ®Google Scholar
• EichhorstBFinkA-MBahloJFirst-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trialLancet Oncol2016177 928 94227216274
   PubMed Web of Science ®Google Scholar
• O’BrienSMKantarjianHThomasDARituximab dose-escalation trial in chronic lymphocytic leukemiaJ Clin Oncol2001198 2165 217011304768
   PubMed Web of Science ®Google Scholar
• ThompsonPATamCSO’BrienSMFludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemiaBlood20161273 303 30926492934
   PubMed Web of Science ®Google Scholar
• ChaudhryMChesonBDWhat is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?Expert Rev Hematol201586 733 74226368831
   PubMed Web of Science ®Google Scholar
• GagezALCartronGObinutuzumab: a new class of anti-CD20 monoclonal antibodyCurr Opin Oncol2014265 484 49125014645
   PubMed Web of Science ®Google Scholar
• GoedeVKleinCStilgenbauerSObinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-Hodgkin’s lymphomas: a glycoengineered type II CD20 antibodyOncol Res Treat2015384 185 19225877943
   PubMed Web of Science ®Google Scholar
• CraggMSWalsheCAIvanovAOGlennieMJThe biology of CD20 and its potential as a target for mAb therapyCurr Dir Autoimmun20058 140 17415564720
   PubMedGoogle Scholar
• WoyachJAJohnsonAJByrdJCThe B-cell receptor signaling pathway as a therapeutic target in CLLBlood20121206 1175 118422715122
   PubMed Web of Science ®Google Scholar
• ChanHTHughesDFrenchRRCD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane raftsCancer Res20036317 5480 548914500384
   PubMed Web of Science ®Google Scholar
• CraggMSMorganSMChanHTComplement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid raftsBlood20031013 1045 105212393541
   PubMed Web of Science ®Google Scholar
• TeelingJLMackusWJWiegmanLJThe biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20J Immunol20061771 362 37116785532
   PubMed Web of Science ®Google Scholar
• HerterSHertingFMundiglOPreclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft modelsMol Cancer Ther20131210 2031 204223873847
   PubMed Web of Science ®Google Scholar
• KernDJJamesBRBlackwellSGassnerCKleinCWeinerGJGA101 induces NK-cell activation and antibody-dependent cellular cytotox-icity more effectively than rituximab when complement is presentLeuk Lymphoma20135411 2500 250523452151
   PubMed Web of Science ®Google Scholar
• LimSHVaughanATAshton-KeyMFc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacyBlood20111189 2530 254021768293
   PubMed Web of Science ®Google Scholar
• MossnerEBrunkerPMoserSIncreasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicityBlood201011522 4393 440220194898
   PubMed Web of Science ®Google Scholar
• AranaEVehlowAHarwoodNEActivation of the small GTPase Rac2 via the B cell receptor regulates B cell adhesion and immunological-synapse formationImmunity2008281 88 9918191593
   PubMed Web of Science ®Google Scholar
• AlduaijWIvanovAHoneychurchJNovel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignanciesBlood201111717 4519 452921378274
   PubMed Web of Science ®Google Scholar
• DalleSReslanLBesseyre de HortsTPreclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101Mol Cancer Ther2011101 178 18521220500
   PubMed Web of Science ®Google Scholar
• IvanovABeersSAWalsheCAMonoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cellsJ Clin Invest20091198 2143 215919620786
   PubMed Web of Science ®Google Scholar
• CheneyCMStephensDMMoXOcaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemiaMAbs201463 749 75524594909
   PubMed Web of Science ®Google Scholar
• NiederfellnerGLammensAMundiglOEpitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodiesBlood20111182 358 36721444918
   PubMed Web of Science ®Google Scholar
• CartronGWatierHGolayJSolal-CelignyPFrom the bench to the bedside: ways to improve rituximab efficacyBlood20041049 2635 264215226177
   PubMed Web of Science ®Google Scholar
• FerraraCGrauSJagerCUnique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucoseProc Natl Acad Sci U S A201110831 12669 1267421768335
   PubMed Web of Science ®Google Scholar
• FerraraCStuartFSondermannPBrunkerPUmanaPThe carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoformsJ Biol Chem20062818 5032 503616330541
   PubMed Web of Science ®Google Scholar
• GolayJDa RoitFBolognaLGlycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximabBlood201312220 3482 349124106207
   PubMed Web of Science ®Google Scholar
• FerraraCBrunkerPSuterTMoserSPuntenerUUmanaPModulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase IIBiotechnol Bioeng2006935 851 86116435400
   PubMed Web of Science ®Google Scholar
• HertingFFriessTBaderSEnhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphomaLeuk Lymphoma2014559 2151 516024304419
   PubMed Web of Science ®Google Scholar
• PatzMIsaevaPForcobNComparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cellsBr J Haematol20111523 295 30621155758
   PubMed Web of Science ®Google Scholar
• CartronGde GuibertSDilhuydyMSObinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN studyBlood201412414 2196 220225143487
   PubMed Web of Science ®Google Scholar
• ByrdJCFlynnJMKippsTJRandomized phase 2 study of obi-nutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemiaBlood20161271 79 8626472752
   PubMed Web of Science ®Google Scholar
• BrownJRO’BrienSKingsleyCDObinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trialBlood201512518 2779 278525769620
   PubMed Web of Science ®Google Scholar
• GoedeVFischerKBuschRObinutuzumab plus chlorambucil in patients with CLL and coexisting conditionsN Engl J Med201437012 1101 111024401022
   PubMed Web of Science ®Google Scholar
• GoedeVFischerKBoschFUpdated Survival Analysis from the CLL11 Study: Obinutuzumab Versus Rituximab in Chemoimmunotherapy-Treated Patients with Chronic Lymphocytic LeukemiaASH Annual Meeting2015Orlando, FL
   Google Scholar
• VitoloUTrněnýMBeladaDObinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)ASH Annual Meeting2016San Diego, CA
   Google Scholar
• MarcusREDaviesAJAndoKObinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM StudyASH Annual Meeting2016San Diego, CA
   Google Scholar
• FreemanCLMFSehnLHDixonMPattern of Cytokine Release in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab and Possible Relationship with Development of Infusion Related Reactions (IRR)San FranciscoASH Annual Meeting2014
   Google Scholar
• FreemanCLDixonMHoughtonRRole of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumabLeukemia2016308 1763 176626979130
   PubMed Web of Science ®Google Scholar
• StilgenbauerSIlhanOWoszczykDSafety and Efficacy of Obinutuzumab Plus Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the Green StudyASH Annual Meeting2015Orlando, FL
   Google Scholar
• CramerPHallekMEichhorstBState-of-the-art treatment and novel agents in chronic lymphocytic leukemiaOncol Res Treat2016391–2 25 3226890007
   PubMed Web of Science ®Google Scholar
• ByrdJCFurmanRRCoutreSEThree-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinibBlood201512516 2497 250625700432
   PubMed Web of Science ®Google Scholar
• KohrtHESagiv-BarfiIRafiqSIbrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicityBlood201412312 1957 196024652965
   PubMed Web of Science ®Google Scholar
• BurgerJAKeatingMJWierdaWGSafety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 studyLancet Oncol20141510 1090 109925150798
   PubMed Web of Science ®Google Scholar
• FurmanRRSharmanJPCoutreSEIdelalisib and rituximab in relapsed chronic lymphocytic leukemiaN Engl J Med201437011 997 100724450857
   PubMed Web of Science ®Google Scholar
• FischerKFinkAMBishopHResults of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions Clinically Relevant AbstractOrlando, FloridaASH 20152015
   Google Scholar
• DavisTACzerwinskiDKLevyRTherapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expressionClin Cancer Res199953 611 61510100713
   PubMed Web of Science ®Google Scholar
• BeumPVKennedyADWilliamsMELindorferMATaylorRPThe shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytesJ Immunol20061764 2600 260916456022
   PubMed Web of Science ®Google Scholar
• HiragaJTomitaASugimotoTDown-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significanceBlood200911320 4885 489319246561
   PubMed Web of Science ®Google Scholar
• KennedyADBeumPVSolgaMDRituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemiaJ Immunol20041725 3280 328814978136
   PubMed Web of Science ®Google Scholar
• CartronGDacheuxLSallesGTherapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa geneBlood2002993 754 75811806974
   PubMed Web of Science ®Google Scholar
• MorschhauserFACartronGThieblemontCObinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN studyJ Clin Oncol20133123 2912 291923835718
   PubMed Web of Science ®Google Scholar
• SallesGAMorschhauserFSolal-CelignyPObinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN studyJ Clin Oncol20133123 2920 292623835715
   PubMed Web of Science ®Google Scholar
• SehnLHChuaNMayerJObinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trialLancet Oncology2016178 1081 109327345636
   PubMed Web of Science ®Google Scholar
• CartronGHourcade-PotelleretFMorschhauserFRationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphomaHaematologica20161012 226 23426659915
   PubMed Web of Science ®Google Scholar
• ReyesCGazauskasGVeentraDCost-effectiveness of obinutuzumab in previously untreated chronic lymphocytic leukemiaMadrid, SpainESMO Annual Meeting2014
   Google Scholar
• JefferisRGlycosylation as a strategy to improve antibody-based therapeuticsNat Rev Drug Discov200983 226 23419247305
   PubMed Web of Science ®Google Scholar
• IllidgeTKleinCSehnLHDaviesASallesGCartronGObinutuzumab in hematologic malignancies: lessons learned to dateCancer Treat Rev2015419 784 79226190254
   PubMed Web of Science ®Google Scholar
• KleinCLammensASchaferWEpitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional propertiesMAbs201351 22 3323211638
   PubMed Web of Science ®Google Scholar
• GoedeVFischerKBuschRChemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-inLeukemia2013275 1172 117422936013
   PubMed Web of Science ®Google Scholar